Affordable Access

deepdyve-link
Publisher Website

Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study.

Authors
  • Reich, K1, 2
  • Sullivan, J3
  • Arenberger, P4
  • Jazayeri, S5
  • Mrowietz, U6
  • Augustin, M7
  • Elewski, B8
  • You, R9
  • Regnault, P10
  • Frueh, J A10
  • 1 Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. , (Germany)
  • 2 Skinflammation® Center, Hamburg, Germany. , (Germany)
  • 3 Sutherland Hospital, University of New South Wales, Sydney, NSW, Australia. , (Australia)
  • 4 Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Prague, Czech Republic. , (Czechia)
  • 5 Alliance Dermatology and Mohs Center, Phoenix, AZ, USA.
  • 6 Psoriasis Center at the Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany. , (Germany)
  • 7 Universität Hamburg, Hamburg, Germany. , (Germany)
  • 8 Department of Dermatology, University of Alabama, Birmingham, AL, USA.
  • 9 China Novartis Institutes for BioMedical Research, Shanghai, China. , (China)
  • 10 Novartis Pharma AG, Basel, Switzerland. , (Switzerland)
Type
Published Article
Journal
British Journal of Dermatology
Publisher
Wiley (Blackwell Publishing)
Publication Date
Mar 01, 2021
Volume
184
Issue
3
Pages
425–436
Identifiers
DOI: 10.1111/bjd.19262
PMID: 32479641
Source
Medline
Language
English
License
Unknown

Abstract

Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, a cornerstone cytokine in psoriasis, has shown long-lasting efficacy and safety in the complete spectrum of psoriasis manifestations. To report the long-term (2·5-year) efficacy and safety of secukinumab in nail psoriasis. TRANSFIGURE, a double-blind, randomized, placebo-controlled, parallel-group, multicentre phase IIIb study in 198 patients, investigated secukinumab 150 mg and 300 mg in patients with moderate-to-severe nail psoriasis. At week 16, the primary endpoint Nail Psoriasis Severity Index (NAPSI) was met, demonstrating superiority of secukinumab to placebo. The effect was sustained over 2·5 years with a large benefit for nail clearance, with mean NAPSI improvement of -73·3% and -63·6% with secukinumab 300 mg and 150 mg, respectively. At 2·5 years, secukinumab demonstrated sustained clinically significant reductions in total mean Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) quality-of-life (QoL) scores of -52·4% and -18·1%, and 70% and 71% of patients achieved a weighted NAPPA Patient Benefit Index global score of ≥ 2 with secukinumab 300 mg and 150 mg, respectively. Patients showed considerable improvements in the EuroQol 5-Dimension health status questionnaire at 2·5 years, reporting a decrease in pain and discomfort. No new safety findings were observed. Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2·5 years in nail psoriasis, with significant sustained QoL improvements and a favourable safety profile. © 2020 British Association of Dermatologists.

Report this publication

Statistics

Seen <100 times